DPX-Survivac: Phase II started

Immunovaccine began an open-label, North American Phase II trial to evaluate subcutaneous DPX-Survivac plus oral cyclophosphamide in up to 24 patients. Subjects will receive 2 doses of DPX-Survivac gi...